SAFETY OF DAPAGLIFLOZIN IN CLINICAL TRIALS FOR TYPE 2 DIABETES MELLITUS

被引：0
|
作者：
Ptaszynska, Agata [2 ]
Johnsson, Kristina [1 ]
Apanovitch, Anne Marie [3 ]
Sugg, Jennifer [4 ]
Parikh, Shamik [4 ]
List, James [2 ]
机构：
[1] AstraZeneca, Molndal, Sweden
[2] Bristol Myers Squibb Co, Princeton, NJ USA
[3] Bristol Myers Squibb Co, Pennington, NJ USA
[4] AstraZeneca, Wilmington, DE USA
来源：
INTERNAL MEDICINE JOURNAL | 2013年 / 43卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [1] Safety of dapagliflozin in clinical trials for type 2 diabetes mellitus
    Johnsson, K.
    Ptaszynska, A.
    Apanovitch, A.
    Sugg, J. E.
    Parikh, S. J.
    List, J. F.
    [J]. DIABETOLOGIA, 2012, 55 : S304 - S304
  • [2] Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
    Jabbour, Serge
    Seufert, Jochen
    Scheen, Andre
    Bailey, Clifford J.
    Karup, Cathrina
    Langkilde, Anna M.
    [J]. DIABETES OBESITY & METABOLISM, 2018, 20 (03): : 620 - 628
  • [3] The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
    Michelle L. O’Donoghue
    Eri T. Kato
    Ofri Mosenzon
    Sabina A. Murphy
    Avivit Cahn
    Marisol Herrera
    Tsvetalina Tankova
    Alena Šmahelová
    Piera Merlini
    Ingrid Gause-Nilsson
    Anna Maria Langkilde
    Darren K. McGuire
    John P. H. Wilding
    Larry A. Leiter
    Deepak L. Bhatt
    Itamar Raz
    Marc S. Sabatine
    Stephen D. Wiviott
    [J]. Diabetologia, 2021, 64 : 1226 - 1234
  • [4] The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus
    O'Donoghue, Michelle L.
    Kato, Eri T.
    Mosenzon, Ofri
    Murphy, Sabina A.
    Cahn, Avivit
    Herrera, Marisol
    Tankova, Tsvetalina
    Smahelova, Alena
    Merlini, Piera
    Gause-Nilsson, Ingrid
    Langkilde, Anna Maria
    McGuire, Darren K.
    Wilding, John P. H.
    Leiter, Larry A.
    Bhatt, Deepak L.
    Raz, Itamar
    Sabatine, Marc S.
    Wiviott, Stephen D.
    [J]. DIABETOLOGIA, 2021, 64 (06) : 1226 - 1234
  • [5] CLINICAL OUTCOMES OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RANDOMISED CONTROLLED CLINICAL TRIALS
    Raval, A.
    Thakker, D.
    Undela, K.
    Vyas, A.
    Kachhadiya, R.
    Ubhadiya, B.
    [J]. VALUE IN HEALTH, 2014, 17 (03) : A240 - A240
  • [6] Efficacy and Safety of Dapagliflozin as Monotherapy for Type 2 Diabetes Mellitus in Japanese Patients
    Kaku, Kohei
    Inoue, Satoshi
    Matsuoka, Osamu
    Kiyosue, Arihiro
    Azuma, Haruna
    Hayashi, Nobuya
    Tokudome, Takuto
    Langkilde, Anna Maria
    Parikh, Shamik
    [J]. DIABETES, 2012, 61 : A260 - A260
  • [7] Dapagliflozin in patients with type 2 diabetes mellitus
    Filippatos, Theodosios D.
    Liberopoulos, Evangelos N.
    Elisaf, Moses S.
    [J]. THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM, 2015, 6 (01) : 29 - 41
  • [8] Dapagliflozin (Farxiga) for Type 2 Diabetes Mellitus
    Pong, Clinton K.
    Maxted, George E.
    [J]. AMERICAN FAMILY PHYSICIAN, 2015, 91 (12) : 828 - +
  • [9] Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus
    Aylsworth, Andrew
    Dean, Zachary
    VanNorman, Cody
    Okere, Arinze Nkemdirim
    [J]. ANNALS OF PHARMACOTHERAPY, 2014, 48 (09) : 1202 - 1208
  • [10] Efficacy and safety of dapagliflozin as monotherapy in patients with type 2 diabetes mellitus A meta-analysis of randomized controlled trials
    Feng, Miao
    Lv, Haihong
    Xu, Xia
    Wang, Jue
    Lyu, Wenyi
    Fu, Songbo
    [J]. MEDICINE, 2019, 98 (30)
12345